Molecular profiling of CCA tumors revealed high genomic heterogeneity, with 40%–50% of patients harboring ≥1 clinically actionable genomic alteration, including alterations in the fibroblast growth factor receptor 2 (FGFR2) gene [1, 4]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.